Pulmonary Function Testing Systems Market Size, Share and Global Trend By System Type (Complete PFT Systems, Portable PFT Systems), By Test Type (Spirometry, Gas Exchange Testing, High Altitude Simulation Testing, Others), By Component (Hardware,Software), By End User (Hospitals & Clinics, Diagnostic Centers) and Geography Forecast till 2022-2029

In March 2019, the association of Breath Diagnostics and Mayo Clinic agreed upon strategic partnership to design and develop new system, which will detect the lung cancer by analysing exhaled breath of the patient. Pulmonary function testing is one of the non-invasive testings which is performed to measure the lung capacity and its functioning. These tests primary includes measure and analysis of lung volume, capacity, gas exchange and rate of breath flow.

Pulmonary function test plays a vital role in in the diagnosis of lung-related disorders such as COPD (Chronic Obstructive Pulmonary Disorders), asthma, and others. Pulmonary function testing provides insights and information about lung’s functioning, such as tidal volume, functional residual capacity, residual volume, total lung capacity, vital capacity, and peak expiratory flow rate amongst others.

To gain extensive insights into the market, Request for Customization

Exponentially increasing prevalence of breathing and lung disorders is expected to boost the growth of the global pulmonary function testing systems market during the forecast period. According to a study conducted by the American Academy of Allergy, Asthma & Immunology, in 2016, an estimated 8.3% of the children in the U.S. were suffering from asthma. Moreover, the range of benefits offered by pulmonary function testing systems in treatment decision making and accuracy in diagnosis is anticipated to offer substantial growth for the global pulmonary testing systems market by 2026.

However, higher acquisition and maintenance cost of the systems and lack of infrastructure in emerging nations are anticipated to hamper the growth of the global pulmonary function testing systems market during the forecast period.

Key Players Covered

Some of the major companies that are present in the global pulmonary function testing systems market are VYAIRE, SCHILLER AMERICAS INC., COSMED srl, MGC Diagnostics Corporation, BD, Ganshorn Medicine Electronic, Medisoft Group, Thorasys, medical equipment Europe GmbH, and others.

SEGMENTATION

Among the segmentation, portable pulmonary function testing system in system type is anticipated to register a significant share owing to better ergonomics and ease of use in the global pulmonary function testing systems market.

Key Insights

• The regulatory scenario for key countries


• New product introduction


• Prevalence of pulmonary diseases for key countries


• Recent industry developments such as partnerships, mergers, and acquisitions

Regional Analysis

North America is anticipated to dominate the global pulmonary function testing systems market owing to developed healthcare infrastructure, increasing the prevalence of pulmonary conditions and higher per capita expenditure. Moreover, growing prevalence of risk factors associated with the pulmonary diseases such as sedentary lifestyle, smoking, lung allergies, and others are anticipated to raise the prevalence of pulmonary conditions, which will eventually boost the growth of the global pulmonary function testing systems market by 2026. The Asia Pacific also holds huge potential for growth of the global pulmonary function testing systems market owing to increasing prevalence of lung disorders. Additionally, growing demand for advanced healthcare devices and systems is projected to offer a favourable environment for the growth of the market in the Asia Pacific.

Key Industry Developments

• In November 2018, Auris Health expanded its investment to increase the sales of newly developed pulmonary function testing medical robot in forthcoming years.
• In January 2018, Owlstone Medical, an U.K. based company invested a substantial amount in designing and development of cancer breathalyser test as well as to develop new devices for patients suffering from idiopathic pulmonary fibrosis.